glp 1 agonists canada CPHA: Now Second-Largest GLP-1 User Market Globally GLP-1 Access in Canada: Options,
Description
As patients lose fat mass, they become more metabolically healthy, reducing strain on multiple organs
Other studies in rodents indicate parallel effects for other addictive drugs including nicotine, opioids, and stimulants
doi: 10.3390/metabo13050587
Zepbound and Mounjaro contain the same active ingredient (tirzepatide) but are approved for different medical conditions-Zepbound for chronic weight management and Mounjaro for type 2 diabetes
Both versions of semaglutide slow digestion, which can cause gastrointestinal (GI) upset
In 2024, SAXENDA generated sales of USD 345 million in the US
